Drug
Aripiprazole Lauroxil
Aripiprazole Lauroxil: highest development phase Post-Market, developed by Alkermes. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Alkermes
Trials
| Drug | Phase | Indication |
|---|---|---|
| Aripiprazole Lauroxil NCT05662306 | Post-Market | Schizophrenia |
| Aripiprazole Lauroxil NCT02634320 | Post-Market | Schizophrenia |
| Aripiprazole Lauroxil NCT02636842 | Phase 1 | Schizophrenia |
Latest
No recent events.
Follow Aripiprazole Lauroxil on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.